[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1996

Bleomycin-Mediated Electrochemotherapy of Metastatic Melanoma

Author Affiliations

From the Division of Dermatology (Drs Glass, Pepine, and Fenske) and Department of Surgery (Drs Jaroszeski, Reintgen, and Heller), University of South Florida College of Medicine, and the Cutaneous Oncology Program, Moffitt Cancer Center, University of South Florida (Drs Glass, Fenske, Reintgen, and Heller), Tampa.

Arch Dermatol. 1996;132(11):1353-1357. doi:10.1001/archderm.1996.03890350095015
Abstract

Background:  Electroporation is a new technique that enhances the antitumor effects of chemotherapy by exposing cancerous tissues to pulses of electricity. When used in combination with conventional chemotherapy, the procedure is termed electrochemotherapy (ECT). The electric pulses increase cell membrane permeability and thus intracellular access. Electrochemotherapy has been shown to have potent antitumor activity in a number of in vitro studies, several animal models, and clinical trials with squamous cell carcinomas and basal cell carcinomas.

Objective:  To report the effects of ECT in 5 patients with metastatic malignant melanoma.

Results:  Twenty-three lesions of metastatic melanoma were treated with intralesional bleomycin sulfate followed by pulses of electricity. Pulses were delivered via caliper or needle electrodes placed around the tumor. Complete responses were observed in 18 tumors (78%) and partial responses were seen in 4 (17%). No responses were seen in lesions treated with either pulses or bleomycin alone. Vital signs were closely monitored during the procedure, and minimal side effects were noted.

Conclusions:  This is the first study that documents the antitumor effects of ECT in metastatic melanoma. Although not a cure, it may be an effective alternative to palliative surgery or irradiation in these patients.Arch Dermatol. 1996;156:1353-1357

×